New radioactive tracer could sharpen cancer scans
NCT ID NCT05989997
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested a new radioactive imaging agent called 68Ga-NOTA-SNA002 in 17 adults with solid tumors. The agent was injected into a vein, and researchers checked its safety, how it spreads in the body, and how well it shows up on PET scans. The goal was to see if this tracer could help doctors better see and understand tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 68Ga-NOTA-SNA002 (a radioactive imaging agent injected into a vein for PET scans)
- What this could lead to
- If successful, this could lead to a new way to see tumors on PET scans, helping doctors diagnose and monitor cancer more accurately.
- What could go wrong
- This is a very early, small Phase 1 trial focused on safety and imaging, not treatment. It may not lead to a widely used diagnostic tool, and the agent could cause side effects or unclear images.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSITRON-EMISSION TOMOGRAPHY(PET) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital Affiliated to Fudan University
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?